Novartis (NYSE: NVS) announced new data showing Cosentyx (secukinumab) delivers efficacy in patients with moderate to severe plaque psoriasis out ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE